Skip to main content
. 2022 Jun 3;20:191. doi: 10.1186/s12916-022-02389-y

Table 2.

Associations of handgrip strength with the risk of cardiometabolic multimorbidity

Unadjusted model Adjusted model
HR (95% CI) P HR (95% CI) P
Participants without any cardiometabolic disease at baseline (Participants=441,868 / CM cases=4,701)
Q4 (highest) 1 (reference) 1 (reference)
Q3 1.32 (1.21–1.45)  < 0.0001 1.08 (0.99–1.19) 0.0943
Q2 1.70 (1.56–1.86)  < 0.0001 1.23 (1.13–1.34)  < 0.0001
Q1 (lowest) 2.41 (2.22–2.62)  < 0.0001 1.46 (1.34–1.60)  < 0.0001
Continuous variablea 1.21 (1.18–1.24)  < 0.0001 1.17 (1.14–1.21)  < 0.0001
Participants with type 2 diabetes at baseline (Participants=18,224 / CM cases=3,505)
Q4 (highest) 1 (reference) 1 (reference)
Q3 1.06 (0.96–1.17) 0.2774 1.01 (0.91–1.11) 0.8936
Q2 1.38 (1.26–1.51)  < 0.0001 1.15 (1.05–1.26) 0.0039
Q1 (lowest) 1.71 (1.56–1.88)  < 0.0001 1.35 (1.23–1.49)  < 0.0001
Continuous variable 1.14 (1.10–1.17)  < 0.0001 1.13 (1.09–1.17)  < 0.0001
Participants with stroke at baseline (Participants=6,092 / CM cases=1,258)
Q4 (highest) 1 (reference) 1 (reference)
Q3 1.02 (0.87–1.20) 0.7725 0.97 (0.82–1.13) 0.6687
Q2 1.24 (1.06–1.45) 0.0068 1.06 (0.90–1.24) 0.4766
Q1 (lowest) 1.53 (1.30–1.80)  < 0.0001 1.23 (1.04–1.46) 0.0159
Continuous variable 1.08 (1.02–1.13)  < 0.0001 1.10 (1.03–1.16) 0.0021
Participants with CHD at baseline (Participants=20,996 / CM cases=3,301)
Q4 (highest) 1 (reference) 1 (reference)
Q3 1.16 (1.05–1.28) 0.0025 1.14 (1.03–1.25) 0.0110
Q2 1.24 (1.13–1.37)  < 0.0001 1.15 (1.05–1.27) 0.0045
Q1 (lowest) 1.42 (1.29–1.57)  < 0.0001 1.23 (1.11–1.36)  < 0.0001
Continuous variable 1.08 (1.04–1.11)  < 0.0001 1.09 (1.05–1.13)  < 0.0001

Adjusted model was adjusted for age, sex, socioeconomic status, ethnicity, smoking status, alcohol drinking, physical activity, BMI and hypertension

aContinuous variable was represented by per standard deviation (SD) decrease of handgrip strength

Abbreviations: HR hazard ratio, CI confidence interval, Q1 the first quartile, Q2 the second quartile, Q3 the third quartile, Q4 the last quartile, CHD coronary heart disease, CM cardiometabolic multimorbidity